ES2538002T3 - Métodos para el tratamiento, la evaluación pronóstica y la detección de cáncer de mama - Google Patents
Métodos para el tratamiento, la evaluación pronóstica y la detección de cáncer de mama Download PDFInfo
- Publication number
- ES2538002T3 ES2538002T3 ES10700222.2T ES10700222T ES2538002T3 ES 2538002 T3 ES2538002 T3 ES 2538002T3 ES 10700222 T ES10700222 T ES 10700222T ES 2538002 T3 ES2538002 T3 ES 2538002T3
- Authority
- ES
- Spain
- Prior art keywords
- breast cancer
- treatment
- methods
- cancer detection
- prognostic evaluation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract description 13
- 208000026310 Breast neoplasm Diseases 0.000 title abstract description 13
- 238000000034 method Methods 0.000 title abstract description 10
- 238000011282 treatment Methods 0.000 title description 8
- 238000001514 detection method Methods 0.000 title description 3
- 238000011156 evaluation Methods 0.000 title description 3
- 238000004393 prognosis Methods 0.000 abstract 2
- 101000591385 Homo sapiens Neurotensin receptor type 1 Proteins 0.000 abstract 1
- 102100033986 Neurotensin receptor type 1 Human genes 0.000 abstract 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 11
- 101800001814 Neurotensin Proteins 0.000 description 10
- 102000050267 Neurotensin Human genes 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 238000009607 mammography Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 3
- 208000004434 Calcinosis Diseases 0.000 description 2
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 1
- 101001008953 Homo sapiens Kinesin-like protein KIF11 Proteins 0.000 description 1
- 102100027629 Kinesin-like protein KIF11 Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/085—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being neurotensin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/44—Multiple drug resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Neurology (AREA)
- Optics & Photonics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
Un método para determinar el pronóstico de un sujeto que padece cáncer de mama, que comprende la etapa de medir el nivel de expresión de receptor 1 de neurotensina (NTRS1) en células cancerosas de mama obtenidas de dicho sujeto, en el que una alta expresión de NTRS1 está asociada con un peor pronóstico.
Description
E10700222
27-05-2015
Métodos para el tratamiento, la evaluación pronóstica y la detección de cáncer de mama
La presente invención se refiere a métodos para el tratamiento, la evaluación pronóstica y la detección de cáncer de mama.
El cáncer de mama es la causa más frecuente de muertas relacionadas con cáncer entre las mujeres en los países occidentales. Entre estas pacientes, una de cada cuatro mujeres muere de cáncer de mama, a pesar de las mejoras en el diagnóstico, la cirugía, la quimioterapia y las nuevas terapias dirigidas. La muerte está asociada con el
15 desarrollo metastásico de la enfermedad. El descubrimiento y caracterización de nuevos contribuyentes sigue siendo necesario para desarrollar tratamientos apropiados y altamente específicos dirigidos al inicio de la metástasis y los procesos de progresión.
Durante 1997, se diagnosticaron más de 36.000 nuevos casos de carcinoma ductal in situ (DCIS), que representa el 17% de todos los nuevos cánceres de mama, en los Estados Unidos. La mayoría de estos casos se diagnosticó por mamografía. Una mamografía de alta calidad es capaz de encontrar una gama de lesiones no invasivas asintomáticas que no puede palparse. Éstas a menudo son más pequeñas, de inferior grado nuclear, y muestran cambios mucho más sutiles que las lesiones detectadas con equipos mamográficos menos avanzados en el pasado. Una mamografía técnicamente buena requiere una atención excepcional al detalle. La necesidad de experta
25 interpretación radiológica no puede enfatizarse lo suficiente. El hallazgo mamográfico más común es las microcalcificaciones, pero algunas lesiones pueden presentase como masas o distorsiones arquitectónicas con o sin microcalcificaciones. La imagen por resonancia magnética (MRI) de mama se ha aprobado por la U.S. Food and Drug Administration (FDA) desde 1991 para su uso como herramienta suplementaria, además de la mamografía, para ayudar a diagnosticar cáncer de mama. La MRI es útil para estadificar el cáncer de mama, lo que determina el tratamiento más apropiado, y para el seguimiento de los pacientes después del tratamiento del cáncer de mama. Como la MRI es más sensible que la mamografía, puede ayudar a detectar cánceres que pueden pasarse por alto por mamografía. Sin embargo, como esta sensibilidad aumentada también puede conducir a resultados falsos positivos, que requiere procedimientos de biopsia de mama, la American Cancer Society no recomienda MRI para todas las mujeres.
35 La neurotensina (NTS) es un péptido de 13 aminoácidos formado a partir de un precursor grande, escindido por convertasas. La NTS es habitualmente conocida por su distribución a lo largo del tracto gastrointestinal. Las funciones fisiológicas típicas para NTS incluyen estimulación de secreciones pancreáticas y biliares, inhibición de la motilidad del intestino delgado y gástrica, y la facilitación de traslocación de ácidos grasos. Igualmente se informó de la NTS en funciones ligadas específicamente a progresión neoplásica, incluyendo proliferación de las células cancerosas de páncreas, próstata, colon, y pulmón. Se ha descrito previamente un papel potencial de NTS en progresión de tumor de mama (Souaze et al (2006) Cancer Res. 66:6243-6249).
Las funciones periféricas de NTS están mediadas a través de su interacción con NTSR1 (receptor 1 de neurotensina 45 de alta afinidad). Cuando NTSR1 se estimula con NTS, los fosfatidil inositoles se hidrolizan conduciendo a movilización de Ca2+ y activación de PKC, ERK1/2, RhoGTPasas, NFkappa-B, y quinasa de adhesión focal (FAK).
El documento US 2005/112678 y el documento WO 2005/052194 describen métodos para el diagnóstico de cánceres en seres humanos utilizando NTSR1.
El documento WO 03/093828 proporciona ensayos para la identificación de compuestos útiles en el tratamiento o prevención de enfermedades cancerosas.
El documento WO 2005/090603 describe métodos para detectar cáncer pulmonar no microcítico usando los genes 55 expresados de forma diferencial KIF11, GHSRIb, NTSR1, y FOXM.
Somai et al: (2002) Biochemical and Biophysical Research Communications 295:482-488 describe métodos para tratar cáncer de mama usando neurotensina.
Garcia-Garayoa (2001) Nuclear Medicine and Biology 28:75-84 describe métodos para el diagnóstico de cáncer usando nuevos análogos de neurotensina.
La identificación de pacientes con fases iniciales patológicas pero con un alto riesgo de recidiva sería extremadamente útil, para adaptar individualmente el tratamiento adicional, en términos de seguimiento más estricto 65 y/o tratamientos adyuvantes.
2
Claims (1)
-
imagen1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09305011 | 2009-01-07 | ||
| EP09305011 | 2009-01-07 | ||
| PCT/EP2010/050044 WO2010079158A1 (en) | 2009-01-07 | 2010-01-05 | Methods for the treatment, the prognostic assessment and the detection of breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2538002T3 true ES2538002T3 (es) | 2015-06-16 |
Family
ID=40380504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10700222.2T Active ES2538002T3 (es) | 2009-01-07 | 2010-01-05 | Métodos para el tratamiento, la evaluación pronóstica y la detección de cáncer de mama |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8586043B2 (es) |
| EP (1) | EP2374003B1 (es) |
| ES (1) | ES2538002T3 (es) |
| WO (1) | WO2010079158A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103308670B (zh) | 2012-03-08 | 2017-06-09 | 思芬构技术有限公司 | 用于预测对象患糖尿病和/或代谢综合征的风险的方法 |
| CN103308673B (zh) | 2012-03-08 | 2017-05-31 | 思芬构技术有限公司 | 用于预测雌性对象中发生心血管事件的风险的方法 |
| CN103308689B (zh) * | 2012-03-08 | 2017-04-12 | 思芬构技术有限公司 | 用于预测雌性对象中患上癌症的风险或诊断癌症的方法 |
| RU2671578C2 (ru) * | 2012-10-02 | 2018-11-02 | Сфинготек Гмбх | Способ прогнозирования риска возникновения рака или диагностирования рака у женщины |
| EP2740726A1 (en) * | 2012-12-07 | 2014-06-11 | 3B Pharmaceuticals GmbH | Neurotensin receptor ligands |
| WO2015158809A1 (en) * | 2014-04-17 | 2015-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancer |
| ES2778251T3 (es) * | 2014-06-02 | 2020-08-10 | Inserm (Institut National De La Santé Et De La Rech Médicale) | Anticuerpos antineurotensina y usos los mismos |
| EP3303391A1 (en) * | 2015-05-26 | 2018-04-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas |
| WO2017012961A1 (en) * | 2015-07-17 | 2017-01-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the prognosis and treatment of endometrial carcinoma |
| EP3850008A1 (en) * | 2018-09-10 | 2021-07-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of an inhibitor of ntsr1 activation or expression for preventing weight loss, muscle loss, and protein blood level decrease in subjects in need thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08502973A (ja) | 1992-11-02 | 1996-04-02 | メルク エンド カンパニー インコーポレーテッド | ニューロテンシンアンタゴニストとしての置換フタラジノン |
| US5760188A (en) | 1992-12-31 | 1998-06-02 | Martin R&F Inc. | Marker for neurotensin receptor |
| US5430047A (en) | 1994-04-07 | 1995-07-04 | Warner-Lambert Company | Neurotensin antagonists |
| FR2720066B1 (fr) | 1994-05-20 | 1996-06-28 | Rhone Poulenc Rorer Sa | Peptides antagonistes de la neurotensine. |
| FR2723317B1 (fr) | 1994-08-04 | 1996-10-31 | Sanofi Sa | Utilisation d'antagonistes de la neurotensine pour la preparation de medicaments diuretiques |
| FR2732967B1 (fr) | 1995-04-11 | 1997-07-04 | Sanofi Sa | 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant |
| US5786213A (en) | 1996-04-18 | 1998-07-28 | Board Of Regents, The University Of Texas System | Inhibition of endogenous gastrin expression for treatment of colorectal cancer |
| WO1998033531A1 (en) | 1997-02-03 | 1998-08-06 | Mallinckrodt Medical, Inc. | Method for the detection and localization of malignant human tumours |
| AU5663199A (en) | 1998-08-07 | 2000-02-28 | Telefonaktiebolaget Lm Ericsson (Publ) | Group addressing in a packet communication system |
| CA2374270A1 (en) | 1999-06-24 | 2000-12-28 | Ananthachari Srinivasan | Labeled neurotensin derivatives |
| WO2003093828A1 (en) | 2002-05-02 | 2003-11-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with neurotensin receptor 1 (nt1) |
| WO2005052194A2 (en) | 2003-11-24 | 2005-06-09 | Amgen Inc. | Gene amplification and overexpression in cancer |
| TW200600785A (en) * | 2004-03-23 | 2006-01-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancer |
| DE102005003687A1 (de) | 2005-01-26 | 2006-07-27 | Sphingo Tec Gmbh | Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation |
| EP1991561B1 (en) | 2006-02-14 | 2015-06-17 | Universita' Degli Studi di Siena | Branched multimeric peptides for tumor diagnosis and therapy |
| WO2008157277A1 (en) * | 2007-06-15 | 2008-12-24 | The University Of North Carolina At Chapel Hill | Methods for evaluating breast cancer prognosis |
-
2010
- 2010-01-05 ES ES10700222.2T patent/ES2538002T3/es active Active
- 2010-01-05 WO PCT/EP2010/050044 patent/WO2010079158A1/en active Application Filing
- 2010-01-05 EP EP10700222.2A patent/EP2374003B1/en active Active
- 2010-01-05 US US13/143,259 patent/US8586043B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20110305633A1 (en) | 2011-12-15 |
| EP2374003A1 (en) | 2011-10-12 |
| WO2010079158A1 (en) | 2010-07-15 |
| US8586043B2 (en) | 2013-11-19 |
| EP2374003B1 (en) | 2015-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2538002T3 (es) | Métodos para el tratamiento, la evaluación pronóstica y la detección de cáncer de mama | |
| Tan et al. | Potential biomarkers for esophageal cancer | |
| Wei et al. | Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases | |
| Lee et al. | Clinical implications of bilateral lateral cervical lymph node metastasis in papillary thyroid cancer: a risk factor for lung metastasis | |
| Ma et al. | Clinical evaluation of tumor markers for diagnosis in patients with non-small cell lung cancer in China | |
| ES2700367T3 (es) | Nuevos biomarcadores para el cáncer de mama metastásico | |
| Dong et al. | Serum carbohydrate antigen 19-9 as an indicator of liver metastasis in colorectal carcinoma cases | |
| Dong et al. | The diagnostic value of 18F-FDG PET/CT in association with serum tumor marker assays in breast cancer recurrence and metastasis | |
| Giganti et al. | Prognostic utility of diffusion-weighted MRI in oesophageal cancer: is apparent diffusion coefficient a potential marker of tumour aggressiveness? | |
| Jansen et al. | Diagnostic use of epitope detection in monocytes blood test for early detection of colon cancer metastasis | |
| Zhou et al. | Elevated preoperative serum CA125 predicts larger tumor diameter in patients with hepatocellular carcinoma and low AFP levels | |
| Zhai et al. | Combination of fluorine-18 fluorodeoxyglucose positron-emission tomography/computed tomography (18F-FDG PET/CT) and tumor markers to diagnose lymph node metastasis in non-small cell lung cancer (NSCLC): a retrospective and prospective study | |
| Yang | Clinical value of serum cancer antigen 19-9 as a tumor screening marker among healthy individuals | |
| Chen et al. | Serum thymidine kinase 1 is a reliable maker for the assessment of the risk of developing malignancy: A case report | |
| Ye et al. | F-18 FDG hypermetabolism in mass-forming focal pancreatitis and old hepatic schistosomiasis with granulomatous inflammation misdiagnosed by PET/CT imaging | |
| Cuppari et al. | 18F-choline PET/CT in leptomeningeal breast cancer metastases | |
| Tavakoli et al. | Gastric cancer diagnosis: from imaging techniques to biochemical biomarkers | |
| Ogino et al. | Lymph node metastases diagnosed by 18F-FDG-PET/CT in esophageal squamous cell cancer treated with concurrent chemoradiotherapy | |
| Lam et al. | Pancreatic metastasis detected by F-18 FDG PET/CT in a patient with breast cancer | |
| Umemura et al. | Serum carcinoembryonic antigen level as a marker for advanced stage and chemotherapeutic response in extramammary paget's disease | |
| Biswas et al. | Clinical Value of Serum Cancer Antigen 19-9 as a Tumor Screening Marker among Healthy Individuals. | |
| RU2411907C1 (ru) | Способ прогнозирования метастазов рака легкого | |
| Yu et al. | Primary malignant melanoma of the esophagus with subtotal esophagectomy: a case report | |
| Mady et al. | From Diagnosis to Remission Navigating Innovative Tumor Markers and Uncovering Hidden Risk in Breast Cancer Care | |
| Yang et al. | Sublingual nodules: Diagnostic markers of metastatic breast cancer |